Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)

Non-alcoholic fatty liver disease (NAFLD) is a series of diseases, involving excessive lipid deposition in the liver and is often accompanied by obesity, diabetes, dyslipidemia, abnormal blood pressure, and other metabolic disorders. In order to more accurately reflect its pathogenesis, an internati...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in endocrinology (Lausanne) Vol. 13; p. 1087260
Main Authors Rong, Li, Zou, Junyan, Ran, Wei, Qi, Xiaohong, Chen, Yaokai, Cui, Hongjuan, Guo, Jinjun
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 16.01.2023
Subjects
Diet
Endocrinology
exercise
Humans
medical treatment
Non-alcoholic Fatty Liver Disease - drug therapy
Non-alcoholic Fatty Liver Disease - therapy
non-alcoholic steatohepatitis
nonalcoholic fatty liver disease
Obesity - metabolism
exercise
medical treatment
nonalcoholic fatty liver disease
diet
non-alcoholic steatohepatitis
Online AccessGet full text

Cover

Abstract Non-alcoholic fatty liver disease (NAFLD) is a series of diseases, involving excessive lipid deposition in the liver and is often accompanied by obesity, diabetes, dyslipidemia, abnormal blood pressure, and other metabolic disorders. In order to more accurately reflect its pathogenesis, an international consensus renamed NAFLD in 2020 as metabolic (dysfunction) associated with fatty liver disease (MAFLD). The changes in diet and lifestyle are recognized the non-drug treatment strategies; however, due to the complex pathogenesis of NAFLD, the current drug therapies are mainly focused on its pathogenic factors, key links of pathogenesis, and related metabolic disorders as targets. There is still a lack of specific drugs. In clinical studies, the common NAFLD treatments include the regulation of glucose and lipid metabolism to protect the liver and anti-inflammation. The NAFLD treatments based on the enterohepatic axis, targeting gut microbiota, are gradually emerging, and various new metabolism-regulating drugs are also under clinical development. Therefore, this review article has comprehensively discussed the research advancements in NAFLD treatment in recent years.
AbstractList Non-alcoholic fatty liver disease (NAFLD) is a series of diseases, involving excessive lipid deposition in the liver and is often accompanied by obesity, diabetes, dyslipidemia, abnormal blood pressure, and other metabolic disorders. In order to more accurately reflect its pathogenesis, an international consensus renamed NAFLD in 2020 as metabolic (dysfunction) associated with fatty liver disease (MAFLD). The changes in diet and lifestyle are recognized the non-drug treatment strategies; however, due to the complex pathogenesis of NAFLD, the current drug therapies are mainly focused on its pathogenic factors, key links of pathogenesis, and related metabolic disorders as targets. There is still a lack of specific drugs. In clinical studies, the common NAFLD treatments include the regulation of glucose and lipid metabolism to protect the liver and anti-inflammation. The NAFLD treatments based on the enterohepatic axis, targeting gut microbiota, are gradually emerging, and various new metabolism-regulating drugs are also under clinical development. Therefore, this review article has comprehensively discussed the research advancements in NAFLD treatment in recent years.
Non-alcoholic fatty liver disease (NAFLD) is a series of diseases, involving excessive lipid deposition in the liver and is often accompanied by obesity, diabetes, dyslipidemia, abnormal blood pressure, and other metabolic disorders. In order to more accurately reflect its pathogenesis, an international consensus renamed NAFLD in 2020 as metabolic (dysfunction) associated with fatty liver disease (MAFLD). The changes in diet and lifestyle are recognized the non-drug treatment strategies; however, due to the complex pathogenesis of NAFLD, the current drug therapies are mainly focused on its pathogenic factors, key links of pathogenesis, and related metabolic disorders as targets. There is still a lack of specific drugs. In clinical studies, the common NAFLD treatments include the regulation of glucose and lipid metabolism to protect the liver and anti-inflammation. The NAFLD treatments based on the enterohepatic axis, targeting gut microbiota, are gradually emerging, and various new metabolism-regulating drugs are also under clinical development. Therefore, this review article has comprehensively discussed the research advancements in NAFLD treatment in recent years.Non-alcoholic fatty liver disease (NAFLD) is a series of diseases, involving excessive lipid deposition in the liver and is often accompanied by obesity, diabetes, dyslipidemia, abnormal blood pressure, and other metabolic disorders. In order to more accurately reflect its pathogenesis, an international consensus renamed NAFLD in 2020 as metabolic (dysfunction) associated with fatty liver disease (MAFLD). The changes in diet and lifestyle are recognized the non-drug treatment strategies; however, due to the complex pathogenesis of NAFLD, the current drug therapies are mainly focused on its pathogenic factors, key links of pathogenesis, and related metabolic disorders as targets. There is still a lack of specific drugs. In clinical studies, the common NAFLD treatments include the regulation of glucose and lipid metabolism to protect the liver and anti-inflammation. The NAFLD treatments based on the enterohepatic axis, targeting gut microbiota, are gradually emerging, and various new metabolism-regulating drugs are also under clinical development. Therefore, this review article has comprehensively discussed the research advancements in NAFLD treatment in recent years.
Author Qi, Xiaohong
Chen, Yaokai
Cui, Hongjuan
Ran, Wei
Zou, Junyan
Rong, Li
Guo, Jinjun
AuthorAffiliation 1 Department of Gastroenterology, Bishan Hospital of Chongqing Medical University, Bishan Hospital of Chongqing , Chongqing , China
3 Medical Research Institute, Southwest University, Public Health Hospital Affiliated to Southwest University , Chongqing , China
4 Department of General surgery, Baoshan People’s Hospital of Yunnan Province , Baoshan, Yunnan , China
2 Medical Research Institute, Southwest University , Chongqing , China
AuthorAffiliation_xml – name: 1 Department of Gastroenterology, Bishan Hospital of Chongqing Medical University, Bishan Hospital of Chongqing , Chongqing , China
– name: 2 Medical Research Institute, Southwest University , Chongqing , China
– name: 3 Medical Research Institute, Southwest University, Public Health Hospital Affiliated to Southwest University , Chongqing , China
– name: 4 Department of General surgery, Baoshan People’s Hospital of Yunnan Province , Baoshan, Yunnan , China
Author_xml – sequence: 1
  givenname: Li
  surname: Rong
  fullname: Rong, Li
– sequence: 2
  givenname: Junyan
  surname: Zou
  fullname: Zou, Junyan
– sequence: 3
  givenname: Wei
  surname: Ran
  fullname: Ran, Wei
– sequence: 4
  givenname: Xiaohong
  surname: Qi
  fullname: Qi, Xiaohong
– sequence: 5
  givenname: Yaokai
  surname: Chen
  fullname: Chen, Yaokai
– sequence: 6
  givenname: Hongjuan
  surname: Cui
  fullname: Cui, Hongjuan
– sequence: 7
  givenname: Jinjun
  surname: Guo
  fullname: Guo, Jinjun
BackLink https://www.ncbi.nlm.nih.gov/pubmed/36726464$$D View this record in MEDLINE/PubMed
BookMark eNp9kUtvGyEUhVGVqnk0f6CLapbpYlxgGAY2lay0SRNZyaZdIx6XmGg8pIAt5d8Xx06VdBE2oMs539HVOUYHU5wAoU8Ez7pOyK8eJhdnFFM6I1gMlON36IhwzlraSXrw4n2ITnO-x_UwTKQUH9Bhx6uBcXaEruduoycLK5hKbsLUlCU0JYEu20kTfVNzWz3auIxjsI3XpTw2Y9hAalzIoDM0Zzfzi8X3Lx_Re6_HDKf7-wT9vvjx6_xnu7i9vDqfL1rbd6y0xjvC6SAFIx4cl73tnSXSDF5bSb0z1HCnZaeNtAY7ZrAfqATvBPYEjOlO0NWO66K-Vw8prHR6VFEH9TSI6U7pVIIdQeG-MntJMBOEYSG0dX4AwXvOHGXSVta3HethbVbgbN056fEV9PXPFJbqLm6UFIIJKirgbA9I8c8aclGrkC2Mo54grrOiw0Akw1T2Vfr5Zda_kOcyqkDsBDbFnBN4ZUPRJcRtdBgVwWpbvXqqXm2rV_vqq5X-Z32mv2H6C8IXszM
CitedBy_id crossref_primary_10_3390_md23010009
crossref_primary_10_1016_j_bioorg_2025_108132
crossref_primary_10_1016_j_jep_2024_118743
crossref_primary_10_1186_s12876_024_03394_6
crossref_primary_10_1111_jcmm_70096
crossref_primary_10_1080_07391102_2023_2256867
crossref_primary_10_1002_ddr_22213
crossref_primary_10_7717_peerj_17011
crossref_primary_10_7759_cureus_72222
crossref_primary_10_1039_D3FO02319B
crossref_primary_10_3748_wjg_v30_i43_4597
crossref_primary_10_1139_facets_2023_0146
crossref_primary_10_3390_ijms26031360
crossref_primary_10_17826_cumj_1520407
crossref_primary_10_1186_s12876_024_03556_6
crossref_primary_10_3390_microorganisms13020241
crossref_primary_10_4014_jmb_2405_05023
crossref_primary_10_1016_j_intimp_2023_111444
crossref_primary_10_3390_antiox13070797
crossref_primary_10_1016_j_biopha_2024_116694
crossref_primary_10_1038_s41387_024_00294_2
crossref_primary_10_3390_ijms25073694
crossref_primary_10_1016_j_diabres_2023_110993
crossref_primary_10_1111_dom_15378
crossref_primary_10_12677_hjmce_2024_124035
crossref_primary_10_1186_s40842_024_00197_2
crossref_primary_10_1007_s13410_024_01419_0
crossref_primary_10_12677_ACM_2024_142348
crossref_primary_10_3390_metabo14040218
crossref_primary_10_1002_fsn3_4638
crossref_primary_10_3390_foods13060948
crossref_primary_10_3389_fphar_2025_1517174
crossref_primary_10_1007_s13659_024_00445_z
crossref_primary_10_4254_wjh_v16_i7_990
crossref_primary_10_2147_DMSO_S448165
crossref_primary_10_1016_j_intimp_2024_113437
crossref_primary_10_1016_j_intimp_2024_113035
crossref_primary_10_1016_j_taap_2024_117185
crossref_primary_10_1016_j_freeradbiomed_2024_03_014
crossref_primary_10_1186_s12889_024_20851_9
crossref_primary_10_1210_clinem_dgae568
crossref_primary_10_3389_fgene_2024_1414835
crossref_primary_10_3748_wjg_v30_i29_3456
crossref_primary_10_3390_antiox13030329
crossref_primary_10_1016_j_pmedr_2024_102798
crossref_primary_10_1186_s12944_024_02108_x
crossref_primary_10_3390_cimb46070376
crossref_primary_10_1186_s12967_024_04942_0
crossref_primary_10_3390_biomedicines12020397
crossref_primary_10_3389_fmicb_2024_1518150
crossref_primary_10_1152_ajpgi_00217_2023
crossref_primary_10_1002_fsn3_4694
crossref_primary_10_22141_2224_0721_20_8_2024_1464
crossref_primary_10_1002_fsn3_4176
crossref_primary_10_1080_07391102_2023_2231544
crossref_primary_10_26599_FMH_2025_9420058
crossref_primary_10_3389_fphar_2024_1419384
crossref_primary_10_1177_17562848231174299
crossref_primary_10_3390_livers3040045
crossref_primary_10_3389_fphar_2024_1463187
crossref_primary_10_1002_mnfr_202300453
crossref_primary_10_12677_acm_2024_1472087
crossref_primary_10_1111_liv_70053
crossref_primary_10_1021_acsomega_3c02347
crossref_primary_10_31146_1682_8658_ecg_229_9_75_85
crossref_primary_10_1186_s40842_024_00187_4
crossref_primary_10_3390_ijms25084397
crossref_primary_10_1038_s41598_025_90419_z
crossref_primary_10_3389_fphys_2024_1428723
crossref_primary_10_1007_s13300_023_01478_2
crossref_primary_10_1097_MEG_0000000000002887
crossref_primary_10_1016_j_phymed_2024_156016
crossref_primary_10_3390_cimb46070399
crossref_primary_10_1111_jcmm_70322
crossref_primary_10_3389_fendo_2023_1138078
crossref_primary_10_1021_acs_jafc_3c08932
crossref_primary_10_1002_fsn3_4155
crossref_primary_10_1016_j_heliyon_2024_e37408
crossref_primary_10_1186_s13104_024_06962_x
crossref_primary_10_3390_ph17070895
crossref_primary_10_2337_dsi23_0010
crossref_primary_10_1007_s12072_024_10698_y
crossref_primary_10_1186_s12933_024_02326_8
crossref_primary_10_2147_IJN_S452194
crossref_primary_10_21518_ms2024_191
crossref_primary_10_1155_2024_5511454
crossref_primary_10_1016_j_saa_2023_123588
crossref_primary_10_1016_j_metabol_2024_155912
crossref_primary_10_4254_wjh_v17_i3_103854
crossref_primary_10_1111_dom_15945
crossref_primary_10_1016_j_lfs_2024_122824
crossref_primary_10_3389_fmed_2025_1509947
crossref_primary_10_3390_biomedicines13030644
crossref_primary_10_1002_fsn3_4267
crossref_primary_10_2147_DMSO_S431251
crossref_primary_10_1016_j_fitote_2024_106186
crossref_primary_10_1016_j_heliyon_2024_e30387
crossref_primary_10_1111_jgh_16662
crossref_primary_10_3390_livers4040046
crossref_primary_10_1186_s12876_025_03612_9
crossref_primary_10_1590_1414_431x2024e13202
crossref_primary_10_1186_s12967_024_05011_2
crossref_primary_10_1016_j_clinre_2023_102229
crossref_primary_10_1097_MEG_0000000000002865
crossref_primary_10_3389_fendo_2024_1290007
crossref_primary_10_57224_jhpr_1555046
crossref_primary_10_1016_j_cbi_2024_111306
crossref_primary_10_3390_medicina60101713
crossref_primary_10_3350_cmh_2024_0315
crossref_primary_10_5114_amsad_202298
Cites_doi 10.1124/jpet.120.265660
10.1111/hepr.12837
10.3390/nu13093192
10.3892/br.2012.18
10.3760/cma.j.cn311367-20200424-00262
10.1053/j.gastro.2020.08.004
10.1515/med-2018-0059
10.3390/nu11122971
10.5114/ceh.2020.102173
10.1016/j.cct.2019.06.017
10.3390/nu13010066
10.1111/apt.16646
10.3389/fendo.2020.609135
10.1007/s00125-013-3149-9
10.1016/s0140-6736(19)32517-6
10.23736/s0026-4806.18.05845-7
10.1002/hep.30590
10.1016/s0140-6736(18)31785-9
10.1093/ajcn/nqy358
10.1016/j.metabol.2016.05.003
10.1002/hep.20092
10.1080/13543784.2020.1718104
10.1016/s1262-3636(17)30070-8
10.1007/s11695-019-04214-7
10.1111/obr.13024
10.1016/j.jhep.2015.02.022
10.1002/dmrr.3292
10.1016/j.jhepr.2021.100412
10.1056/NEJMoa2036205
10.1242/dmm.048884
10.1002/hep.31886
10.3390/ijms22157841
10.1016/j.soard.2018.03.019
10.1007/s10620-011-1887-4
10.3390/ijms222313105
10.1053/j.gastro.2013.05.042
10.1053/j.gastro.2021.07.025
10.1016/j.metabol.2015.12.012
10.1172/jci150996
10.1080/09637486.2021.1979478
10.1001/jama.2018.20579
10.1038/s41598-022-10481-9
10.15403/jgld.2014.1121.271.kby
10.1016/j.jhep.2018.08.011
10.1002/hep4.2005
10.4103/2008-7802.178533
10.1111/apt.16596
10.3760/cma.j.issn.1007-3418.2018.01.009
10.1016/s0140-6736(14)61933-4
10.1016/j.jhep.2017.05.016
10.1016/j.diabres.2021.108984
10.1111/apt.15316
10.1016/j.jhep.2018.11.032
10.1111/liv.14350
10.1016/j.phrs.2014.03.002
10.1016/j.jhep.2010.10.009
10.2337/dci19-0066
10.3945/ajcn.113.068890
10.1016/s2468-1253(22)00017-6
10.1136/bmj.i4428
10.1007/s11695-017-3012-z
10.2337/dc18-1569
10.1038/s41598-019-40322-1
10.2337/dc17-0518
10.2169/internalmedicine.4398-19
10.1002/hep.29367
10.1097/mco.0000000000000762
10.3389/fcimb.2022.759306
10.1016/s2213-8587(18)30154-2
10.1007/s00394-018-1721-2
10.1038/s41467-022-29968-0
10.1080/14740338.2019.1602116
10.1111/dom.14319
10.1111/ijpo.12872
10.3390/cells8030253
10.1097/mcg.0000000000001503
10.1016/j.jhep.2010.08.030
10.1007/s11154-013-9253-9
10.1111/dom.13907
10.1016/j.cgh.2006.09.025
10.5009/gnl20367
10.1111/dme.13697
10.1056/NEJMc1306659
10.1111/apt.15427
10.3969/j.issn.1005-3697.2021.12.014
10.1016/s0140-6736(19)33041-7
10.12669/pjms.38.1.4968
10.1038/s41575-020-00396-z
10.1007/s00535-010-0291-8
10.1016/j.bbadis.2014.02.004
10.1056/NEJMoa2028395
10.1111/dom.13520
10.1007/s12325-020-01498-5
10.1111/liv.15005
10.1056/NEJMoa060326
10.1038/nrgastro.2016.170
10.1111/apt.15989
10.1073/pnas.1922344117
10.1016/j.gastrohep.2012.06.004
10.1038/s41575-020-0269-9
10.1055/s-0041-1723751
10.1056/NEJMoa0907929
10.1111/jgh.15363
10.1016/s0140-6736(18)30474-4
10.7326/m15-1774
10.1038/s41440-018-0040-6
10.3760/cma.j.issn.0254-1432.2020.01.017
10.1002/hep.30076
10.1016/j.numecd.2022.01.024
10.7759/cureus.6605
10.3164/jcbn.20-129
10.2174/1871530321666210225110140
10.3760/cma.j.cn501113-20210430-00215
10.1016/j.molmet.2020.101152
10.1210/jc.2016-2775
10.1017/s000711451800137x
10.1053/j.gastro.2016.10.007
10.1186/s12916-022-02288-2
10.1007/s00125-018-4675-2
10.1002/dmrr.2561
10.1016/j.jhep.2015.11.004
10.1089/jmf.2011.0075
10.1111/apt.16608
10.1016/j.imr.2014.09.007
10.1007/s10620-021-07317-3
10.1002/hep4.1696
10.1002/oby.22344
10.1002/hep4.1657
10.1111/dom.14263
10.3390/nu13030966
10.1038/nature13270
10.1002/hep.31000
10.1002/hep.31843
10.1097/md.0000000000020399
10.1007/s00125-020-05265-7
10.1053/j.gastro.2008.06.047
10.1096/fba.2018-00044
10.1111/dom.14670
10.1053/j.gastro.2016.01.038
10.1016/j.cgh.2020.10.051
10.1590/s0004-27302013000900005
10.3748/wjg.v27.i10.959
10.1155/2015/706416
10.1096/fj.202001495R
10.1002/hep4.1019
10.1002/hep.30670
10.1210/jc.2017-00867
10.1038/s41374-017-0018-z
10.14309/ajg.0000000000000845
10.14309/ajg.0000000000000661
10.1016/j.redox.2020.101635
10.1111/liv.14799
10.1016/j.cgh.2017.04.039
10.1080/13543784.2020.1708898
10.1038/ajg.2010.299
10.1097/md.0000000000019471
10.1111/bph.15427
10.3904/kjim.2017.194
10.5223/pghn.2013.16.1.22
10.1152/ajpendo.00266.2017
10.1016/s0140-6736(15)00803-x
10.14218/jcth.2014.00037
10.1038/labinvest.2012.103
10.2337/dc19-0641
10.3748/wjg.v25.i4.509
10.1016/j.jhep.2012.02.023
10.2174/1381612825666190117114305
10.1016/j.jnutbio.2010.10.002
10.1038/s41598-021-04361-x
10.1186/s40360-021-00524-8
10.1016/j.numecd.2017.03.001
10.1080/07315724.2015.1031355
10.1111/1753-0407.12555
10.2174/1570161115666170621082910
10.1186/s12933-021-01237-2
10.1111/apt.16664
10.1097/meg.0000000000001191
10.1038/s41598-019-43228-0
10.1136/gutjnl-2020-323106
ContentType Journal Article
Copyright Copyright © 2023 Rong, Zou, Ran, Qi, Chen, Cui and Guo.
Copyright © 2023 Rong, Zou, Ran, Qi, Chen, Cui and Guo 2023 Rong, Zou, Ran, Qi, Chen, Cui and Guo
Copyright_xml – notice: Copyright © 2023 Rong, Zou, Ran, Qi, Chen, Cui and Guo.
– notice: Copyright © 2023 Rong, Zou, Ran, Qi, Chen, Cui and Guo 2023 Rong, Zou, Ran, Qi, Chen, Cui and Guo
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOA
DOI 10.3389/fendo.2022.1087260
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
CrossRef


MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1664-2392
ExternalDocumentID oai_doaj_org_article_05ac959104814088acdf7e86564d249c
PMC9884828
36726464
10_3389_fendo_2022_1087260
Genre Research Support, Non-U.S. Gov't
Journal Article
Review
GrantInformation_xml – fundername: ;
  grantid: 2022GDRC019
– fundername: ;
  grantid: CSTB2022NSCQ-MSX1257
GroupedDBID 53G
5VS
9T4
AAFWJ
AAKDD
AAYXX
ACGFO
ACGFS
ACXDI
ADBBV
ADRAZ
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
CITATION
DIK
EMOBN
GROUPED_DOAJ
GX1
HYE
KQ8
M48
M~E
OK1
PGMZT
RPM
CGR
CUY
CVF
ECM
EIF
IAO
IEA
IHR
IHW
IPNFZ
NPM
RIG
7X8
5PM
ID FETCH-LOGICAL-c534t-bfd16279841fed695c5dc19b7fac92fdb2b6da93ab9cb0d4b0f729efd80f1ebb3
IEDL.DBID M48
ISSN 1664-2392
IngestDate Wed Aug 27 01:27:42 EDT 2025
Thu Aug 21 18:38:15 EDT 2025
Fri Jul 11 12:43:50 EDT 2025
Thu Jan 02 22:54:18 EST 2025
Thu Apr 24 23:07:44 EDT 2025
Tue Jul 01 01:41:36 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords exercise
medical treatment
nonalcoholic fatty liver disease
diet
non-alcoholic steatohepatitis
Language English
License Copyright © 2023 Rong, Zou, Ran, Qi, Chen, Cui and Guo.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c534t-bfd16279841fed695c5dc19b7fac92fdb2b6da93ab9cb0d4b0f729efd80f1ebb3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
This article was submitted to Gut Endocrinology, a section of the journal Frontiers in Endocrinology
Edited by: Andrea Dalbeni, Verona University Hospital, Italy
These authors have contributed equally to this work and share first authorship
Reviewed by: Hua-Tian Gan, Sichuan University, China; Zou Min, Chongqing General Hospital, China
OpenAccessLink https://doaj.org/article/05ac959104814088acdf7e86564d249c
PMID 36726464
PQID 2771940295
PQPubID 23479
ParticipantIDs doaj_primary_oai_doaj_org_article_05ac959104814088acdf7e86564d249c
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9884828
proquest_miscellaneous_2771940295
pubmed_primary_36726464
crossref_citationtrail_10_3389_fendo_2022_1087260
crossref_primary_10_3389_fendo_2022_1087260
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-01-16
PublicationDateYYYYMMDD 2023-01-16
PublicationDate_xml – month: 01
  year: 2023
  text: 2023-01-16
  day: 16
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
PublicationTitle Frontiers in endocrinology (Lausanne)
PublicationTitleAlternate Front Endocrinol (Lausanne)
PublicationYear 2023
Publisher Frontiers Media S.A
Publisher_xml – name: Frontiers Media S.A
References Seko (B63) 2017; 47
Gastaldelli (B68) 2020; 22
Shi (B8) 2020; 40
Anekwe (B22) 2020; 12
Watanabe (B19) 2020; 21
Taheri (B77) 2020; 37
Mohamad Nor (B151) 2021; 13
Park (B117) 2011; 46
Li (B91) 2013; 1
Pinyopornpanish (B95) 2021; 15
Buzzetti (B1) 2016; 65
Cusi (B51) 2019; 69
Madiraju (B88) 2014; 510
Pratt (B42) 2018; 14
Akuta (B70) 2022; 6
Sepideh (B148) 2016; 35
Loomba (B180) 2021; 161
Colosimo (B69) 2021; 41
Takahashi (B80) 2022; 6
Kannt (B165) 2021; 178
Athyros (B105) 2018; 16
Syed-Abdul (B179) 2020; 72
Lee (B118) 2019; 34
Katsagoni (B12) 2018; 120
Biolato (B14) 2019; 25
Akbari (B159) 2021; 22
Hassani Zadeh (B6) 2021; 36
Chauhan (B44) 2022; 67
Van der Graaff (B120) 2018; 98
Liu (B66) 2020; 36
Noto (B119) 2022; 32
Dichtel (B60) 2021; 74
Zhang (B102) 2015; 3
Bomhof (B152) 2019; 58
Harreiter (B94) 2021; 23
Belfort (B100) 2006; 355
Harrison (B172) 2021; 160
Shao (B142) 2021; 29
Ito (B78) 2017; 40
Hajifathalian (B110) 2022; 56
Crabtree (B23) 2021; 13
Huber (B34) 2019; 50
Aller (B145) 2011; 15
Doumas (B111) 2018; 24
Asgharian (B155) 2016; 7
Buse (B89) 2020; 43
Haedrich (B129) 2011; 54
Kahl (B75) 2020; 43
Harrison (B166) 2019; 394
Gaborit (B74) 2021; 20
Petit (B50) 2017
Cusi (B71) 2016; 165
Foster (B107) 2011; 106
Risi (B5) 2021; 24
Henson (B109) 2021; 54
Kim (B104) 2017; 15
Muyyarikkandy (B21) 2020; 34
Nguyen (B46) 2017; 14
Takeshita (B116) 2014; 57
Stefan (B143) 2019; 7
Harrison (B170) 2018; 391
Keating (B37) 2012; 57
Gao (B38) 2020; 36
Harrison (B171) 2020; 71
Kobyliak (B149) 2018; 27
Xue (B157) 2022; 12
Francque (B161) 2021; 385
Akuta (B85) 2017; 1
Nickel (B45) 2018; 28
Sirtori (B101) 2014; 88
Gastaldelli (B162) 2021; 41
Ratziu (B137) 2019; 84
Kawaguchi (B16) 2021; 41
Francque (B121) 2012; 92
Ratziu (B132) 2011; 54
Talukdar (B169) 2021; 46
Properzi (B13) 2018; 68
Newsome (B56) 2019; 50
Fan (B64) 2013; 57
Verzijl (B178) 2020; 29
Aithal (B99) 2008; 135
Yaskolka Meir (B39) 2021; 70
Cusi (B61) 2018; 35
Bril (B112) 2017; 102
Jia (B30) 2018; 26
Cusi (B96) 2020
Newsome (B57) 2021; 384
Petit (B53) 2017; 102
Chalasani (B43) 2018; 67
Siddiqui (B158) 2021; 19
Gawrieh (B160) 2021; 74
Kobyliak (B150) 2018; 109
Shao (B65) 2014; 30
Brouwers (B28) 2018; 314
Harrison (B173) 2022; 7
Schwimmer (B26) 2019; 321
(B2) 2016; 64
Markova (B24) 2017; 152
Tanaka (B114) 2020; 374
Younossi (B138) 2019; 394
Casula (B113) 2017; 27
van der Graaff (B122) 2022; 4
Glen (B4) 2016; 354
Yurtdaş (B18) 2022; 17
Shimizu (B83) 2019; 21
Miyake (B79) 2018; 13
Latva-Rasku (B81) 2019; 42
Charles (B176) 2019; 27
Safadi (B181) 2021; 54
Sanyal (B177) 2019; 392
Franco (B41) 2020; 13
Flint (B59) 2021; 54
Takahashi (B31) 2020; 99
Nadinskaia (B133) 2021; 27
Eriksson (B82) 2018; 61
Esposito (B10) 2013; 369
Lindor (B130) 2004; 39
Toyoda (B115) 2019; 1
Harrison (B167) 2021; 5
Wong (B29) 2018; 69
Katsiki (B103) 2016; 65
Park (B126) 2019; 9
Mitrovic (B93) 2022; 22
Lee (B106) 2021; 116
Dwinata (B73) 2020; 6
Dufour (B128) 2006; 4
Park (B141) 2013; 16
Chen (B146) 2019; 109
Malaguarnera (B153) 2012; 57
Wong (B72) 2020; 11
Unsal (B67) 2022; 12
Komorizono (B92) 2021; 23
Della Pepa (B97) 2021; 178
Ritchie (B175) 2020; 29
Dickson (B58) 2021; 18
Borém (B127) 2018; 41
Caddeo (B168) 2021; 22
Sanyal (B98) 2010; 362
Luukkonen (B20) 2020; 117
Romero-Gómez (B15) 2017; 67
Neuschwander-Tetri (B136) 2015; 385
Kuchay (B62) 2020; 63
Chen (B131) 2019; 8
Feng (B55) 2017; 9
Abdelbasset (B36) 2020; 99
Eslamparast (B154) 2014; 99
Wang (B125) 2021; 22
Chalasani (B3) 2018; 67
Ali (B49) 2022; 38
Sagredo (B47) 2013; 36
Oikonomou (B123) 2018; 30
Tobita (B84) 2021; 68
Brandt (B90) 2019; 9
Ratziu (B163) 2016; 150
Rinella (B174) 2019; 70
So (B27) 2014; 3
Jinnouchi (B52) 2015; 2015
Mudaliar (B135) 2013; 145
Kahl (B76) 2022; 24
Cheng (B40) 2022; 13
Plaz Torres (B7) 2019; 11
Scheen (B87) 2019; 18
Aron-Wisnewsky (B140) 2020; 17
Iacono (B139) 2011; 22
Nakajima (B164) 2021; 54
Cho (B108) 2022; 20
Keating (B35) 2015; 63
Bravo (B124) 2021; 14
O'Gorman (B32) 2020; 52
Akbulut (B17) 2022; 73
Akuta (B86) 2020; 59
Armstrong (B54) 2016; 387
Cohen (B25) 2021; 131
Craven (B156) 2020; 115
Gao (B147) 2021; 36
Hao (B144) 2020; 40
Esposito (B9) 2013; 14
Younus (B48) 2020; 30
Pérez-Guisado (B11) 2011; 14
Babu (B33) 2022; 12
Kunne (B134) 2014; 1842
References_xml – volume: 374
  year: 2020
  ident: B114
  article-title: Ezetimibe markedly reduces hepatic triglycerides and cholesterol in rats fed on fish oil by increasing the expression of cholesterol efflux transporters
  publication-title: J Pharmacol Exp Ther
  doi: 10.1124/jpet.120.265660
– volume: 47
  year: 2017
  ident: B63
  article-title: Effect of 12-week dulaglutide therapy in Japanese patients with biopsy-proven non-alcoholic fatty liver disease and type 2 diabetes mellitus
  publication-title: Hepatol Res Off J Japan Soc Hepatol
  doi: 10.1111/hepr.12837
– volume: 13
  start-page: 3192
  year: 2021
  ident: B151
  article-title: The effect of probiotics (Mcp(®) bcmc(®) strains) on hepatic steatosis, small intestinal mucosal immune function, and intestinal barrier in patients with non-alcoholic fatty liver disease
  publication-title: Nutrients
  doi: 10.3390/nu13093192
– volume: 1
  start-page: 57
  year: 2013
  ident: B91
  article-title: Metformin in non-alcoholic fatty liver disease: A systematic review and meta-analysis
  publication-title: Biomed Rep
  doi: 10.3892/br.2012.18
– volume: 40
  year: 2020
  ident: B8
  article-title: Non-drug therapy of non-alcoholic fatty liver disease
  publication-title: Chin J Dig
  doi: 10.3760/cma.j.cn311367-20200424-00262
– volume: 160
  start-page: 219
  year: 2021
  ident: B172
  article-title: Efficacy and safety of aldafermin, an engineered Fgf19 analog, in a randomized, double-blind, placebo-controlled trial of patients with nonalcoholic steatohepatitis
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2020.08.004
– volume: 13
  year: 2018
  ident: B79
  article-title: Ipragliflozin ameliorates liver damage in non-alcoholic fatty liver disease
  publication-title: Open Med (Warsaw Poland)
  doi: 10.1515/med-2018-0059
– volume: 11
  start-page: 2971
  year: 2019
  ident: B7
  article-title: Mediterranean Diet and nafld: What we know and questions that still need to be answered
  publication-title: Nutrients
  doi: 10.3390/nu11122971
– volume: 6
  year: 2020
  ident: B73
  article-title: Sglt2 inhibitors for improving hepatic fibrosis and steatosis in non-alcoholic fatty liver disease complicated with type 2 diabetes mellitus: A systematic review
  publication-title: Clin Exp Hepatol
  doi: 10.5114/ceh.2020.102173
– volume: 84
  start-page: 105803
  year: 2019
  ident: B137
  article-title: Regenerate: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis
  publication-title: Contemp Clin trials
  doi: 10.1016/j.cct.2019.06.017
– volume: 13
  start-page: 66
  year: 2020
  ident: B41
  article-title: Physical activity and low glycemic index Mediterranean diet: Main and modification effects on nafld score. Results from a randomized clinical trial
  publication-title: Nutrients
  doi: 10.3390/nu13010066
– volume: 54
  year: 2021
  ident: B109
  article-title: Trends in statin utilisation in us adults with non-alcoholic fatty liver disease
  publication-title: Aliment Pharmacol Ther
  doi: 10.1111/apt.16646
– volume: 11
  year: 2020
  ident: B72
  article-title: Sodium-glucose Co-transporter 2 inhibitors for non-alcoholic fatty liver disease in Asian patients with type 2 diabetes: A meta-analysis
  publication-title: Front Endocrinol
  doi: 10.3389/fendo.2020.609135
– volume: 57
  year: 2014
  ident: B116
  article-title: The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: A randomised controlled trial
  publication-title: Diabetologia
  doi: 10.1007/s00125-013-3149-9
– volume: 394
  year: 2019
  ident: B166
  article-title: Resmetirom (Mgl-3196) for the treatment of non-alcoholic steatohepatitis: A multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
  publication-title: Lancet (London England)
  doi: 10.1016/s0140-6736(19)32517-6
– volume: 109
  year: 2018
  ident: B150
  article-title: Beneficial effects of probiotic combination with omega-3 fatty acids in nafld: A randomized clinical study
  publication-title: Minerva Med
  doi: 10.23736/s0026-4806.18.05845-7
– volume: 71
  year: 2020
  ident: B171
  article-title: Ngm282 improves liver fibrosis and histology in 12 weeks in patients with nonalcoholic steatohepatitis
  publication-title: Hepatology
  doi: 10.1002/hep.30590
– volume: 392
  year: 2019
  ident: B177
  article-title: Pegbelfermin (Bms-986036), a pegylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: A randomised, double-blind, placebo-controlled, phase 2a trial
  publication-title: Lancet (London England)
  doi: 10.1016/s0140-6736(18)31785-9
– volume: 109
  year: 2019
  ident: B146
  article-title: Yogurt improves insulin resistance and liver fat in obese women with nonalcoholic fatty liver disease and metabolic syndrome: A randomized controlled trial
  publication-title: Am J Clin Nutr
  doi: 10.1093/ajcn/nqy358
– volume: 65
  year: 2016
  ident: B103
  article-title: Non-alcoholic fatty liver disease and dyslipidemia: An update
  publication-title: Metabolism
  doi: 10.1016/j.metabol.2016.05.003
– volume: 39
  year: 2004
  ident: B130
  article-title: Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial
  publication-title: Hepatology
  doi: 10.1002/hep.20092
– volume: 29
  start-page: 197
  year: 2020
  ident: B175
  article-title: Fibroblast growth factor (Fgf)-21 based therapies: A magic bullet for nonalcoholic fatty liver disease (Nafld)
  publication-title: Expert Opin investigat Drugs
  doi: 10.1080/13543784.2020.1718104
– year: 2017
  ident: B50
  article-title: Glp-1 receptor agonists in nafld
  publication-title: Diabetes Metab
  doi: 10.1016/s1262-3636(17)30070-8
– volume: 30
  year: 2020
  ident: B48
  article-title: Bariatric surgery in cirrhotic patients: Is it safe
  publication-title: Obes Surg
  doi: 10.1007/s11695-019-04214-7
– volume: 21
  start-page: e13024
  year: 2020
  ident: B19
  article-title: Beneficial effects of the ketogenic diet on nonalcoholic fatty liver disease: A comprehensive review of the literature
  publication-title: Obes Rev an Off J Int Assoc Study Obes
  doi: 10.1111/obr.13024
– volume: 63
  year: 2015
  ident: B35
  article-title: Effect of aerobic exercise training dose on liver fat and visceral adiposity
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2015.02.022
– volume: 36
  start-page: e3292
  year: 2020
  ident: B66
  article-title: Efficacy of exenatide and insulin glargine on nonalcoholic fatty liver disease in patients with type 2 diabetes
  publication-title: Diabetes/metab Res Rev
  doi: 10.1002/dmrr.3292
– volume: 4
  year: 2022
  ident: B122
  article-title: Vasoconstrictor antagonism improves functional and structural vascular alterations and liver damage in rats with early nafld
  publication-title: JHEP Rep
  doi: 10.1016/j.jhepr.2021.100412
– volume: 385
  year: 2021
  ident: B161
  article-title: A randomized, controlled trial of the pan-ppar agonist lanifibranor in Nash
  publication-title: New Engl J Med
  doi: 10.1056/NEJMoa2036205
– volume: 14
  start-page: dmm048884
  year: 2021
  ident: B124
  article-title: Synergic effect of atorvastatin and ambrisentan on sinusoidal and hemodynamic alterations in a rat model of Nash
  publication-title: Dis Models Mech
  doi: 10.1242/dmm.048884
– volume: 74
  year: 2021
  ident: B60
  article-title: The glucagon-like peptide-1 receptor agonist, semaglutide, for the treatment of nonalcoholic steatohepatitis
  publication-title: Hepatology
  doi: 10.1002/hep.31886
– volume: 22
  start-page: 7841
  year: 2021
  ident: B125
  article-title: Losartan prevents hepatic steatosis and macrophage polarization by inhibiting hif-1α in a murine model of nafld
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms22157841
– volume: 14
  start-page: 882
  year: 2018
  ident: B42
  article-title: Asmbs pediatric metabolic and bariatric surgery guidelines, 2018
  publication-title: Surg Obes related Dis Off J Am Soc Bariatric Surg
  doi: 10.1016/j.soard.2018.03.019
– volume: 57
  year: 2012
  ident: B153
  article-title: Bifidobacterium longum with fructo-oligosaccharides in patients with non alcoholic steatohepatitis
  publication-title: Dig Dis Sci
  doi: 10.1007/s10620-011-1887-4
– volume: 22
  start-page: 13105
  year: 2021
  ident: B168
  article-title: Tg68, a novel thyroid hormone receptor-B agonist for the treatment of nafld
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms222313105
– volume: 145
  start-page: 574
  year: 2013
  ident: B135
  article-title: Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2013.05.042
– volume: 161
  year: 2021
  ident: B180
  article-title: Tvb-2640 (Fasn inhibitor) for the treatment of nonalcoholic steatohepatitis: Fascinate-1, a randomized, placebo-controlled phase 2a trial
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2021.07.025
– volume: 65
  year: 2016
  ident: B1
  article-title: The multiple-hit pathogenesis of non-alcoholic fatty liver disease (Nafld)
  publication-title: Metabolism
  doi: 10.1016/j.metabol.2015.12.012
– volume: 131
  year: 2021
  ident: B25
  article-title: Dietary sugar restriction reduces hepatic De novo lipogenesis in adolescent boys with fatty liver disease
  publication-title: J Clin Invest
  doi: 10.1172/jci150996
– volume: 73
  year: 2022
  ident: B17
  article-title: The effect of a Mediterranean diet vs. a low-fat diet on non-alcoholic fatty liver disease in children: A randomized trial
  publication-title: Int J Food Sci Nutr
  doi: 10.1080/09637486.2021.1979478
– volume: 321
  year: 2019
  ident: B26
  article-title: Effect of a low free sugar diet vs usual diet on nonalcoholic fatty liver disease in adolescent boys: A randomized clinical trial
  publication-title: Jama
  doi: 10.1001/jama.2018.20579
– volume: 12
  start-page: 6485
  year: 2022
  ident: B33
  article-title: Effects of exercise on nafld using non-targeted metabolomics in adipose tissue, plasma, urine, and stool
  publication-title: Sci Rep
  doi: 10.1038/s41598-022-10481-9
– volume: 27
  year: 2018
  ident: B149
  article-title: A multi-strain probiotic reduces the fatty liver index, cytokines and aminotransferase levels in nafld patients: Evidence from a randomized clinical trial
  publication-title: J gastrointestinal liver Dis JGLD
  doi: 10.15403/jgld.2014.1121.271.kby
– volume: 69
  year: 2018
  ident: B29
  article-title: Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2018.08.011
– volume: 6
  year: 2022
  ident: B70
  article-title: Favorable impact of long-term Sglt2 inhibitor for nafld complicated by diabetes mellitus: A 5-year follow-up study
  publication-title: Hepatol Commun
  doi: 10.1002/hep4.2005
– volume: 7
  start-page: 59
  year: 2016
  ident: B155
  article-title: The effect of symbiotic supplementation on liver enzymes, c-reactive protein and ultrasound findings in patients with non-alcoholic fatty liver disease: A clinical trial
  publication-title: Int J Prev Med
  doi: 10.4103/2008-7802.178533
– volume: 54
  year: 2021
  ident: B164
  article-title: Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor A modulator (Spparmα), versus placebo in patients with non-alcoholic fatty liver disease
  publication-title: Aliment Pharmacol Ther
  doi: 10.1111/apt.16596
– volume: 26
  start-page: 34
  year: 2018
  ident: B30
  article-title: [Effect of aerobic exercise and resistance exercise in improving non-alcoholic fatty liver disease: A randomized controlled trial]
  publication-title: Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chin J Hepatol
  doi: 10.3760/cma.j.issn.1007-3418.2018.01.009
– volume: 385
  year: 2015
  ident: B136
  article-title: Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (Flint): A multicentre, randomised, placebo-controlled trial
  publication-title: Lancet (London England)
  doi: 10.1016/s0140-6736(14)61933-4
– volume: 67
  year: 2017
  ident: B15
  article-title: Treatment of nafld with diet, physical activity and exercise
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2017.05.016
– volume: 178
  year: 2021
  ident: B97
  article-title: Pioglitazone even at low dosage improves nafld in type 2 diabetes: Clinical and pathophysiological insights from a subgroup of the Tosca.It randomised trial
  publication-title: Diabetes Res Clin Pract
  doi: 10.1016/j.diabres.2021.108984
– volume: 50
  start-page: 193
  year: 2019
  ident: B56
  article-title: Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity
  publication-title: Aliment Pharmacol Ther
  doi: 10.1111/apt.15316
– volume: 70
  year: 2019
  ident: B174
  article-title: Rosuvastatin improves the Fgf19 analogue Ngm282-associated lipid changes in patients with non-alcoholic steatohepatitis
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2018.11.032
– year: 2020
  ident: B96
  article-title: A diabetologist's perspective of non-alcoholic steatohepatitis (Nash): Knowledge gaps and future directions
  publication-title: Liver Int
  doi: 10.1111/liv.14350
– volume: 88
  start-page: 3
  year: 2014
  ident: B101
  article-title: The pharmacology of statins
  publication-title: Pharmacol Res
  doi: 10.1016/j.phrs.2014.03.002
– volume: 54
  year: 2011
  ident: B129
  article-title: Udca for Nash: End of the story
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2010.10.009
– volume: 43
  year: 2020
  ident: B89
  article-title: 2019 Update to: Management of hyperglycemia in type 2 diabetes, 2018. a consensus report by the American diabetes association (Ada) and the European association for the study of diabetes (Easd)
  publication-title: Diabetes Care
  doi: 10.2337/dci19-0066
– volume: 99
  year: 2014
  ident: B154
  article-title: Synbiotic supplementation in nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled pilot study
  publication-title: Am J Clin Nutr
  doi: 10.3945/ajcn.113.068890
– volume: 7
  year: 2022
  ident: B173
  article-title: Aldafermin in patients with non-alcoholic steatohepatitis (Alpine 2/3): A randomised, double-blind, placebo-controlled, phase 2b trial
  publication-title: Lancet Gastroenterol Hepatol
  doi: 10.1016/s2468-1253(22)00017-6
– volume: 354
  year: 2016
  ident: B4
  article-title: Non-alcoholic fatty liver disease (Nafld): Summary of nice guidance
  publication-title: BMJ (Clinical Res ed
  doi: 10.1136/bmj.i4428
– volume: 28
  year: 2018
  ident: B45
  article-title: Bariatric surgery as an efficient treatment for non-alcoholic fatty liver disease in a prospective study with 1-year follow-up : Bariscan study
  publication-title: Obes Surg
  doi: 10.1007/s11695-017-3012-z
– volume: 42
  year: 2019
  ident: B81
  article-title: The Sglt2 inhibitor dapagliflozin reduces liver fat but does not affect tissue insulin sensitivity: A randomized, double-blind, placebo-controlled study with 8-week treatment in type 2 diabetes patients
  publication-title: Diabetes Care
  doi: 10.2337/dc18-1569
– volume: 9
  start-page: 4003
  year: 2019
  ident: B126
  article-title: Connectivity mapping of angiotensin-ppar interactions involved in the amelioration of non-alcoholic steatohepatitis by telmisartan
  publication-title: Sci Rep
  doi: 10.1038/s41598-019-40322-1
– volume: 40
  year: 2017
  ident: B78
  article-title: Comparison of ipragliflozin and pioglitazone effects on nonalcoholic fatty liver disease in patients with type 2 diabetes: A randomized, 24-week, open-label, active-controlled trial
  publication-title: Diabetes Care
  doi: 10.2337/dc17-0518
– volume: 59
  year: 2020
  ident: B86
  article-title: Sglt2 inhibitor treatment outcome in nonalcoholic fatty liver disease complicated with diabetes mellitus: The long-term effects on clinical features and liver histopathology
  publication-title: Internal Med (Tokyo Japan)
  doi: 10.2169/internalmedicine.4398-19
– volume: 67
  year: 2018
  ident: B3
  article-title: The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American association for the study of liver diseases
  publication-title: Hepatology
  doi: 10.1002/hep.29367
– volume: 24
  year: 2021
  ident: B5
  article-title: Beyond weight loss in nonalcoholic fatty liver disease: The role of carbohydrate restriction
  publication-title: Curr Opin Clin Nutr Metab Care
  doi: 10.1097/mco.0000000000000762
– volume: 12
  year: 2022
  ident: B157
  article-title: Effect of fecal microbiota transplantation on non-alcoholic fatty liver disease: A randomized clinical trial
  publication-title: Front Cell infection Microbiol
  doi: 10.3389/fcimb.2022.759306
– volume: 7
  year: 2019
  ident: B143
  article-title: Non-alcoholic fatty liver disease: Causes, diagnosis, cardiometabolic consequences, and treatment strategies
  publication-title: Lancet Diabetes Endocrinol
  doi: 10.1016/s2213-8587(18)30154-2
– volume: 58
  year: 2019
  ident: B152
  article-title: Histological improvement of non-alcoholic steatohepatitis with a prebiotic: A pilot clinical trial
  publication-title: Eur J Nutr
  doi: 10.1007/s00394-018-1721-2
– volume: 13
  start-page: 2555
  year: 2022
  ident: B40
  article-title: A randomized controlled trial for response of microbiome network to exercise and diet intervention in patients with nonalcoholic fatty liver disease
  publication-title: Nat Commun
  doi: 10.1038/s41467-022-29968-0
– volume: 18
  start-page: 295
  year: 2019
  ident: B87
  article-title: An update on the safety of Sglt2 inhibitors
  publication-title: Expert Opin Drug Saf
  doi: 10.1080/14740338.2019.1602116
– volume: 23
  year: 2021
  ident: B94
  article-title: Combined exenatide and dapagliflozin has no additive effects on reduction of hepatocellular lipids despite better glycaemic control in patients with type 2 diabetes mellitus treated with metformin: Exenda, a 24-week, prospective, randomized, placebo-controlled pilot trial
  publication-title: Diabetes Obes Metab
  doi: 10.1111/dom.14319
– volume: 17
  start-page: e12872
  year: 2022
  ident: B18
  article-title: The effects of Mediterranean diet on hepatic steatosis, oxidative stress, and inflammation in adolescents with non-alcoholic fatty liver disease: A randomized controlled trial
  publication-title: Pediatr Obes
  doi: 10.1111/ijpo.12872
– volume: 8
  start-page: 253
  year: 2019
  ident: B131
  article-title: Ursodeoxycholic acid regulates hepatic energy homeostasis and white adipose tissue macrophages polarization in leptin-deficiency obese mice
  publication-title: Cells
  doi: 10.3390/cells8030253
– volume: 56
  year: 2022
  ident: B110
  article-title: Effect of statin use on cancer-related mortality in nonalcoholic fatty liver disease: A prospective united states cohort study
  publication-title: J Clin Gastroenterol
  doi: 10.1097/mcg.0000000000001503
– volume: 54
  year: 2011
  ident: B132
  article-title: A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2010.08.030
– volume: 14
  year: 2013
  ident: B9
  article-title: Mediterranean Diet and metabolic syndrome: An updated systematic review
  publication-title: Rev Endocrine Metab Disord
  doi: 10.1007/s11154-013-9253-9
– volume: 22
  start-page: 393
  year: 2020
  ident: B68
  article-title: Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes
  publication-title: Diabetes Obes Metab
  doi: 10.1111/dom.13907
– volume: 4
  year: 2006
  ident: B128
  article-title: Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis
  publication-title: Clin Gastroenterol Hepatol
  doi: 10.1016/j.cgh.2006.09.025
– volume: 15
  year: 2021
  ident: B95
  article-title: Effects of metformin on hepatic steatosis in adults with nonalcoholic fatty liver disease and diabetes: Insights from the cellular to patient levels
  publication-title: Gut liver
  doi: 10.5009/gnl20367
– volume: 35
  year: 2018
  ident: B61
  article-title: Dulaglutide decreases plasma aminotransferases in people with type 2 diabetes in a pattern consistent with liver fat reduction: A Post hoc analysis of the award programme
  publication-title: Diabetic Med J Br Diabetic Assoc
  doi: 10.1111/dme.13697
– volume: 369
  year: 2013
  ident: B10
  article-title: Mediterranean Diet for primary prevention of cardiovascular disease
  publication-title: New Engl J Med
  doi: 10.1056/NEJMc1306659
– volume: 50
  year: 2019
  ident: B34
  article-title: Improvement of non-invasive markers of nafld from an individualised, web-based exercise program
  publication-title: Aliment Pharmacol Ther
  doi: 10.1111/apt.15427
– volume: 36
  start-page: 1597
  year: 2021
  ident: B147
  article-title: Effects of intestinal flora regulation therapy on liver function and blood lipid metabolism in patients with non-alcoholic fatty liver
  publication-title: J North Sichuan Med Coll
  doi: 10.3969/j.issn.1005-3697.2021.12.014
– volume: 394
  year: 2019
  ident: B138
  article-title: Obeticholic acid for the treatment of non-alcoholic steatohepatitis: Interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
  publication-title: Lancet (London England)
  doi: 10.1016/s0140-6736(19)33041-7
– volume: 38
  start-page: 28
  year: 2022
  ident: B49
  article-title: Frequency of non-alcoholic fatty liver disease (Nafld) and its associated risk factors among type-2 diabetics
  publication-title: Pak J Med Sci
  doi: 10.12669/pjms.38.1.4968
– volume: 18
  year: 2021
  ident: B58
  article-title: Semaglutide is safe and efficacious for Nash resolution
  publication-title: Nat Rev Gastroenterol Hepatol
  doi: 10.1038/s41575-020-00396-z
– volume: 46
  year: 2011
  ident: B117
  article-title: Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease
  publication-title: J Gastroenterol
  doi: 10.1007/s00535-010-0291-8
– volume: 1842
  year: 2014
  ident: B134
  article-title: Fxr-dependent reduction of hepatic steatosis in a bile salt deficient mouse model
  publication-title: Biochim Biophys Acta
  doi: 10.1016/j.bbadis.2014.02.004
– volume: 384
  year: 2021
  ident: B57
  article-title: A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
  publication-title: New Engl J Med
  doi: 10.1056/NEJMoa2028395
– volume: 21
  year: 2019
  ident: B83
  article-title: Evaluation of the effects of dapagliflozin, a sodium-glucose Co-Transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease
  publication-title: Diabetes Obes Metab
  doi: 10.1111/dom.13520
– volume: 37
  year: 2020
  ident: B77
  article-title: Effect of empagliflozin on liver steatosis and fibrosis in patients with non-alcoholic fatty liver disease without diabetes: A randomized, double-blind, placebo-controlled trial
  publication-title: Adv Ther
  doi: 10.1007/s12325-020-01498-5
– volume: 41
  year: 2021
  ident: B162
  article-title: Ppar-Γ-Induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with Nash
  publication-title: Liver Int
  doi: 10.1111/liv.15005
– volume: 355
  year: 2006
  ident: B100
  article-title: A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
  publication-title: New Engl J Med
  doi: 10.1056/NEJMoa060326
– volume: 14
  year: 2017
  ident: B46
  article-title: Bariatric surgery for obesity and metabolic disorders: State of the art
  publication-title: Nat Rev Gastroenterol Hepatol
  doi: 10.1038/nrgastro.2016.170
– volume: 15
  year: 2011
  ident: B145
  article-title: Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: A double blind randomized clinical trial
  publication-title: Eur Rev Med Pharmacol Sci
– volume: 52
  year: 2020
  ident: B32
  article-title: Improvement in histological endpoints of mafld following a 12-week aerobic exercise intervention
  publication-title: Aliment Pharmacol Ther
  doi: 10.1111/apt.15989
– volume: 117
  year: 2020
  ident: B20
  article-title: Effect of a ketogenic diet on hepatic steatosis and hepatic mitochondrial metabolism in nonalcoholic fatty liver disease
  publication-title: Proc Natl Acad Sci United States America
  doi: 10.1073/pnas.1922344117
– volume: 36
  start-page: 76
  year: 2013
  ident: B47
  article-title: [Acute liver failure after bariatric surgery. a case report and literature review]
  publication-title: Gastroenterol y hepatol
  doi: 10.1016/j.gastrohep.2012.06.004
– volume: 17
  year: 2020
  ident: B140
  article-title: Gut microbiota and human nafld: Disentangling microbial signatures from metabolic disorders
  publication-title: Nat Rev Gastroenterol Hepatol
  doi: 10.1038/s41575-020-0269-9
– volume: 41
  year: 2021
  ident: B16
  article-title: Effects of Mediterranean diet in patients with nonalcoholic fatty liver disease: A systematic review, meta-analysis, and meta-regression analysis of randomized controlled trials
  publication-title: Semin liver Dis
  doi: 10.1055/s-0041-1723751
– volume: 362
  year: 2010
  ident: B98
  article-title: Pioglitazone, vitamin e, or placebo for nonalcoholic steatohepatitis
  publication-title: New Engl J Med
  doi: 10.1056/NEJMoa0907929
– volume: 36
  year: 2021
  ident: B6
  article-title: Relationship between dietary patterns and non-alcoholic fatty liver disease: A systematic review and meta-analysis
  publication-title: J Gastroenterol Hepatol
  doi: 10.1111/jgh.15363
– volume: 391
  year: 2018
  ident: B170
  article-title: Ngm282 for treatment of non-alcoholic steatohepatitis: A multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
  publication-title: Lancet (London England)
  doi: 10.1016/s0140-6736(18)30474-4
– volume: 165
  year: 2016
  ident: B71
  article-title: Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: A randomized trial
  publication-title: Ann Internal Med
  doi: 10.7326/m15-1774
– volume: 41
  start-page: 394
  year: 2018
  ident: B127
  article-title: The role of the angiotensin ii type I receptor blocker telmisartan in the treatment of non-alcoholic fatty liver disease: A brief review
  publication-title: Hypertension Res Off J Japanese Soc Hypertension
  doi: 10.1038/s41440-018-0040-6
– volume: 40
  start-page: 69
  year: 2020
  ident: B144
  article-title: Role of the gut microbiota in the diagnosis and treatment of hepatobiliary diseases
  publication-title: Chin J Dig
  doi: 10.3760/cma.j.issn.0254-1432.2020.01.017
– volume: 68
  year: 2018
  ident: B13
  article-title: Ad libitum Mediterranean and low-fat diets both significantly reduce hepatic steatosis: A randomized controlled trial
  publication-title: Hepatology
  doi: 10.1002/hep.30076
– volume: 32
  year: 2022
  ident: B119
  article-title: Lifestyle versus ezetimibe plus lifestyle in patients with biopsy-proven non-alcoholic steatohepatitis (Listen): A double-blind randomised placebo-controlled trial
  publication-title: Nutrition Metab Cardiovasc Dis NMCD
  doi: 10.1016/j.numecd.2022.01.024
– volume: 12
  year: 2020
  ident: B22
  article-title: Ketogenic diet-induced elevated cholesterol, elevated liver enzymes and potential non-alcoholic fatty liver disease
  publication-title: Cureus
  doi: 10.7759/cureus.6605
– volume: 68
  year: 2021
  ident: B84
  article-title: Comparison of dapagliflozin and teneligliptin in nonalcoholic fatty liver disease patients without type 2 diabetes mellitus: A prospective randomized study
  publication-title: J Clin Biochem Nutr
  doi: 10.3164/jcbn.20-129
– volume: 22
  year: 2022
  ident: B93
  article-title: Effects of metformin-single therapy on the level of inflammatory markers in serum of non-obese T2dm patients with nafld
  publication-title: Endocr Metab Immune Disord Drug Targets
  doi: 10.2174/1871530321666210225110140
– volume: 29
  year: 2021
  ident: B142
  article-title: Role of gut-liver-immune axis in the pathogenesis of nonalcoholic steatohepatitis
  publication-title: Chin J Hep
  doi: 10.3760/cma.j.cn501113-20210430-00215
– volume: 46
  year: 2021
  ident: B169
  article-title: Fgf19 and Fgf21: In Nash we trust
  publication-title: Mol Metab
  doi: 10.1016/j.molmet.2020.101152
– volume: 102
  year: 2017
  ident: B53
  article-title: Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes: The lira-nafld study
  publication-title: J Clin Endocrinol Metab
  doi: 10.1210/jc.2016-2775
– volume: 120
  year: 2018
  ident: B12
  article-title: Improvements in clinical characteristics of patients with non-alcoholic fatty liver disease, after an intervention based on the Mediterranean lifestyle: A randomised controlled clinical trial
  publication-title: Br J Nutr
  doi: 10.1017/s000711451800137x
– volume: 152
  start-page: 571
  year: 2017
  ident: B24
  article-title: Isocaloric diets high in animal or plant protein reduce liver fat and inflammation in individuals with type 2 diabetes
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2016.10.007
– volume: 20
  start-page: 93
  year: 2022
  ident: B108
  article-title: Ezetimibe combination therapy with statin for non-alcoholic fatty liver disease: An open-label randomized controlled trial (Essential study)
  publication-title: BMC Med
  doi: 10.1186/s12916-022-02288-2
– volume: 61
  year: 2018
  ident: B82
  article-title: Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: A double-blind randomised placebo-controlled study
  publication-title: Diabetologia
  doi: 10.1007/s00125-018-4675-2
– volume: 30
  year: 2014
  ident: B65
  article-title: Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes
  publication-title: Diabetes/metab Res Rev
  doi: 10.1002/dmrr.2561
– volume: 64
  year: 2016
  ident: B2
  article-title: Easl-Easd-Easo clinical practice guidelines for the management of non-alcoholic fatty liver disease
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2015.11.004
– volume: 14
  year: 2011
  ident: B11
  article-title: The effect of the Spanish ketogenic Mediterranean diet on nonalcoholic fatty liver disease: A pilot study
  publication-title: J Med Food
  doi: 10.1089/jmf.2011.0075
– volume: 54
  year: 2021
  ident: B59
  article-title: Randomised clinical trial: Semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging
  publication-title: Aliment Pharmacol Ther
  doi: 10.1111/apt.16608
– volume: 3
  year: 2014
  ident: B27
  article-title: Exercise-induced myokines in health and metabolic diseases
  publication-title: Integr Med Res
  doi: 10.1016/j.imr.2014.09.007
– volume: 67
  year: 2022
  ident: B44
  article-title: Bariatric surgery in nafld
  publication-title: Dig Dis Sci
  doi: 10.1007/s10620-021-07317-3
– volume: 6
  year: 2022
  ident: B80
  article-title: Ipragliflozin improves the hepatic outcomes of patients with diabetes with nafld
  publication-title: Hepatol Commun
  doi: 10.1002/hep4.1696
– volume: 27
  year: 2019
  ident: B176
  article-title: Pegbelfermin (Bms-986036), pegylated Fgf21, in patients with obesity and type 2 diabetes: Results from a randomized phase 2 study
  publication-title: Obes (Silver Spring Md)
  doi: 10.1002/oby.22344
– volume: 5
  year: 2021
  ident: B167
  article-title: Effects of resmetirom on noninvasive endpoints in a 36-week phase 2 active treatment extension study in patients with Nash
  publication-title: Hepatol Commun
  doi: 10.1002/hep4.1657
– volume: 23
  year: 2021
  ident: B92
  article-title: Metformin dose increase versus added linagliptin in non-alcoholic fatty liver disease and type 2 diabetes: An analysis of the J-link study
  publication-title: Diabetes Obes Metab
  doi: 10.1111/dom.14263
– volume: 13
  start-page: 966
  year: 2021
  ident: B23
  article-title: Comparison of ketogenic diets with and without ketone salts versus a low-fat diet: Liver fat responses in overweight adults
  publication-title: Nutrients
  doi: 10.3390/nu13030966
– volume: 510
  year: 2014
  ident: B88
  article-title: Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase
  publication-title: Nature
  doi: 10.1038/nature13270
– volume: 72
  year: 2020
  ident: B179
  article-title: Fatty acid synthase inhibitor tvb-2640 reduces hepatic De novo lipogenesis in males with metabolic abnormalities
  publication-title: Hepatology
  doi: 10.1002/hep.31000
– volume: 74
  year: 2021
  ident: B160
  article-title: Saroglitazar, a ppar-A/Γ agonist, for treatment of nafld: A randomized controlled double-blind phase 2 trial
  publication-title: Hepatology
  doi: 10.1002/hep.31843
– volume: 99
  year: 2020
  ident: B31
  article-title: Simple resistance exercise decreases cytokeratin 18 and fibroblast growth factor 21 levels in patients with nonalcoholic fatty liver disease: A retrospective clinical study
  publication-title: Medicine
  doi: 10.1097/md.0000000000020399
– volume: 63
  year: 2020
  ident: B62
  article-title: Effect of dulaglutide on liver fat in patients with type 2 diabetes and nafld: Randomised controlled trial (D-lift trial)
  publication-title: Diabetologia
  doi: 10.1007/s00125-020-05265-7
– volume: 135
  year: 2008
  ident: B99
  article-title: Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2008.06.047
– volume: 1
  year: 2019
  ident: B115
  article-title: Identification of hepatic Npc1l1 as an nafld risk factor evidenced by ezetimibe-mediated steatosis prevention and recovery
  publication-title: FASEB bioAdvances
  doi: 10.1096/fba.2018-00044
– volume: 24
  year: 2022
  ident: B76
  article-title: Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes
  publication-title: Diabetes Obes Metab
  doi: 10.1111/dom.14670
– volume: 150
  start-page: 1147
  year: 2016
  ident: B163
  article-title: Elafibranor, an agonist of the peroxisome proliferator-activated receptor-A and -Δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2016.01.038
– volume: 19
  year: 2021
  ident: B158
  article-title: A phase 2 double blinded, randomized controlled trial of saroglitazar in patients with nonalcoholic steatohepatitis
  publication-title: Clin Gastroenterol Hepatol
  doi: 10.1016/j.cgh.2020.10.051
– volume: 57
  year: 2013
  ident: B64
  article-title: Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease
  publication-title: Arquivos brasileiros endocrinol e metabol
  doi: 10.1590/s0004-27302013000900005
– volume: 27
  year: 2021
  ident: B133
  article-title: Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease
  publication-title: World J Gastroenterol
  doi: 10.3748/wjg.v27.i10.959
– volume: 2015
  year: 2015
  ident: B52
  article-title: Liraglutide, a glucagon-like peptide-1 analog, increased insulin sensitivity assessed by hyperinsulinemic-euglycemic clamp examination in patients with uncontrolled type 2 diabetes mellitus
  publication-title: J Diabetes Res
  doi: 10.1155/2015/706416
– volume: 34
  year: 2020
  ident: B21
  article-title: Branched chain amino acids and carbohydrate restriction exacerbate ketogenesis and hepatic mitochondrial oxidative dysfunction during nafld
  publication-title: FASEB J Off Publ Fed Am Societies Exp Biol
  doi: 10.1096/fj.202001495R
– volume: 1
  start-page: 46
  year: 2017
  ident: B85
  article-title: Effects of a sodium-glucose cotransporter 2 inhibitor in nonalcoholic fatty liver disease complicated by diabetes mellitus: Preliminary prospective study based on serial liver biopsies
  publication-title: Hepatol Commun
  doi: 10.1002/hep4.1019
– volume: 69
  year: 2019
  ident: B51
  article-title: Incretin-based therapies for the management of nonalcoholic fatty liver disease in patients with type 2 diabetes
  publication-title: Hepatology
  doi: 10.1002/hep.30670
– volume: 102
  year: 2017
  ident: B112
  article-title: Liver safety of statins in prediabetes or T2dm and nonalcoholic steatohepatitis: Post hoc analysis of a randomized trial
  publication-title: J Clin Endocrinol Metab
  doi: 10.1210/jc.2017-00867
– volume: 98
  year: 2018
  ident: B120
  article-title: Severe steatosis induces portal hypertension by systemic arterial hyporeactivity and hepatic vasoconstrictor hyperreactivity in rats
  publication-title: Lab investigat J Tech Methods Pathol
  doi: 10.1038/s41374-017-0018-z
– volume: 116
  year: 2021
  ident: B106
  article-title: Effects of statin use on the development and progression of nonalcoholic fatty liver disease: A nationwide nested case-control study
  publication-title: Am J Gastroenterol
  doi: 10.14309/ajg.0000000000000845
– volume: 115
  year: 2020
  ident: B156
  article-title: Allogenic fecal microbiota transplantation in patients with nonalcoholic fatty liver disease improves abnormal small intestinal permeability: A randomized control trial
  publication-title: Am J Gastroenterol
  doi: 10.14309/ajg.0000000000000661
– volume: 36
  year: 2020
  ident: B38
  article-title: Exercise and dietary intervention ameliorate high-fat diet-induced nafld and liver aging by inducing lipophagy
  publication-title: Redox Biol
  doi: 10.1016/j.redox.2020.101635
– volume: 41
  year: 2021
  ident: B69
  article-title: Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes: A real-world data analysis
  publication-title: Liver Int
  doi: 10.1111/liv.14799
– volume: 15
  start-page: 1521
  year: 2017
  ident: B104
  article-title: Statin use and risk of cirrhosis and related complications in patients with chronic liver diseases: A systematic review and meta-analysis
  publication-title: Clin Gastroenterol Hepatol
  doi: 10.1016/j.cgh.2017.04.039
– volume: 29
  year: 2020
  ident: B178
  article-title: Pegbelfermin (Bms-986036): An investigational pegylated fibroblast growth factor 21 analogue for the treatment of nonalcoholic steatohepatitis
  publication-title: Expert Opin investigat Drugs
  doi: 10.1080/13543784.2020.1708898
– volume: 106
  year: 2011
  ident: B107
  article-title: Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: The St Francis heart study randomized clinical trial
  publication-title: Am J Gastroenterol
  doi: 10.1038/ajg.2010.299
– volume: 99
  start-page: e19471
  year: 2020
  ident: B36
  article-title: Effects of high-intensity interval and moderate-intensity continuous aerobic exercise on diabetic obese patients with nonalcoholic fatty liver disease: A comparative randomized controlled trial
  publication-title: Medicine
  doi: 10.1097/md.0000000000019471
– volume: 178
  year: 2021
  ident: B165
  article-title: Activation of thyroid hormone receptor-B improved disease activity and metabolism independent of body weight in a mouse model of non-alcoholic steatohepatitis and fibrosis
  publication-title: Br J Pharmacol
  doi: 10.1111/bph.15427
– volume: 34
  start-page: 296
  year: 2019
  ident: B118
  article-title: Ezetimibe decreased nonalcoholic fatty liver disease activity score but not hepatic steatosis
  publication-title: Korean J Internal Med
  doi: 10.3904/kjim.2017.194
– volume: 16
  year: 2013
  ident: B141
  article-title: Gut microbiota and clinical disease: Obesity and nonalcoholic fatty liver disease
  publication-title: Pediatr gastroenterol Hepatol Nutr
  doi: 10.5223/pghn.2013.16.1.22
– volume: 314
  year: 2018
  ident: B28
  article-title: Exercise training reduces intrahepatic lipid content in people with and people without nonalcoholic fatty liver
  publication-title: Am J Physiol Endocrinol Metab
  doi: 10.1152/ajpendo.00266.2017
– volume: 387
  year: 2016
  ident: B54
  article-title: Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (Lean): A multicentre, double-blind, randomised, placebo-controlled phase 2 study
  publication-title: Lancet (London England)
  doi: 10.1016/s0140-6736(15)00803-x
– volume: 67
  year: 2018
  ident: B43
  article-title: The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
  publication-title: Hepatology
  doi: 10.1002/hep.29367
– volume: 3
  start-page: 78
  year: 2015
  ident: B102
  article-title: Nonalcoholic fatty liver disease: Dyslipidemia, risk for cardiovascular complications, and treatment strategy
  publication-title: J Clin Trans Hepatol
  doi: 10.14218/jcth.2014.00037
– volume: 92
  year: 2012
  ident: B121
  article-title: Increased intrahepatic resistance in severe steatosis: Endothelial dysfunction, vasoconstrictor overproduction and altered microvascular architecture
  publication-title: Lab investigat J Tech Methods Pathol
  doi: 10.1038/labinvest.2012.103
– volume: 43
  start-page: 298
  year: 2020
  ident: B75
  article-title: Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: A randomized, double-blind, phase 4, placebo-controlled trial
  publication-title: Diabetes Care
  doi: 10.2337/dc19-0641
– volume: 25
  year: 2019
  ident: B14
  article-title: Intestinal permeability after Mediterranean diet and low-fat diet in non-alcoholic fatty liver disease
  publication-title: World J Gastroenterol
  doi: 10.3748/wjg.v25.i4.509
– volume: 57
  year: 2012
  ident: B37
  article-title: Exercise and non-alcoholic fatty liver disease: A systematic review and meta-analysis
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2012.02.023
– volume: 24
  year: 2018
  ident: B111
  article-title: The role of statins in the management of nonalcoholic fatty liver disease
  publication-title: Curr Pharm design
  doi: 10.2174/1381612825666190117114305
– volume: 22
  start-page: 699
  year: 2011
  ident: B139
  article-title: Probiotics as an emerging therapeutic strategy to treat nafld: Focus on molecular and biochemical mechanisms
  publication-title: J Nutr Biochem
  doi: 10.1016/j.jnutbio.2010.10.002
– volume: 12
  start-page: 283
  year: 2022
  ident: B67
  article-title: Evaluation of nafld fibrosis, fib-4 and apri score in diabetic patients receiving exenatide treatment for non-alcoholic fatty liver disease
  publication-title: Sci Rep
  doi: 10.1038/s41598-021-04361-x
– volume: 22
  start-page: 53
  year: 2021
  ident: B159
  article-title: Saroglitazar improved hepatic steatosis and fibrosis by modulating inflammatory cytokines and adiponectin in an animal model of non-alcoholic steatohepatitis
  publication-title: BMC Pharmacol Toxicol
  doi: 10.1186/s40360-021-00524-8
– volume: 27
  start-page: 396
  year: 2017
  ident: B113
  article-title: Statin use and risk of new-onset diabetes: A meta-analysis of observational studies
  publication-title: Nutrition Metab Cardiovasc Dis NMCD
  doi: 10.1016/j.numecd.2017.03.001
– volume: 35
  year: 2016
  ident: B148
  article-title: Effects of multistrain probiotic supplementation on glycemic and inflammatory indices in patients with nonalcoholic fatty liver disease: A double-blind randomized clinical trial
  publication-title: J Am Coll Nutr
  doi: 10.1080/07315724.2015.1031355
– volume: 9
  year: 2017
  ident: B55
  article-title: Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease
  publication-title: J Diabetes
  doi: 10.1111/1753-0407.12555
– volume: 16
  year: 2018
  ident: B105
  article-title: Statins: An under-appreciated asset for the prevention and the treatment of nafld or Nash and the related cardiovascular risk
  publication-title: Curr Vasc Pharmacol
  doi: 10.2174/1570161115666170621082910
– volume: 20
  start-page: 57
  year: 2021
  ident: B74
  article-title: Effect of empagliflozin on ectopic fat stores and myocardial energetics in type 2 diabetes: The empacef study
  publication-title: Cardiovasc Diabetol
  doi: 10.1186/s12933-021-01237-2
– volume: 54
  year: 2021
  ident: B181
  article-title: Randomised clinical trial: A phase 2 double-blind study of namodenoson in non-alcoholic fatty liver disease and steatohepatitis
  publication-title: Aliment Pharmacol Ther
  doi: 10.1111/apt.16664
– volume: 30
  year: 2018
  ident: B123
  article-title: Non-alcoholic fatty liver disease and hypertension: Coprevalent or correlated
  publication-title: Eur J Gastroenterol Hepatol
  doi: 10.1097/meg.0000000000001191
– volume: 9
  start-page: 6668
  year: 2019
  ident: B90
  article-title: Metformin attenuates the onset of non-alcoholic fatty liver disease and affects intestinal microbiota and barrier in small intestine
  publication-title: Sci Rep
  doi: 10.1038/s41598-019-43228-0
– volume: 70
  year: 2021
  ident: B39
  article-title: Effect of green-Mediterranean diet on intrahepatic fat: The direct plus randomised controlled trial
  publication-title: Gut
  doi: 10.1136/gutjnl-2020-323106
SSID ssj0000401998
Score 2.6227229
SecondaryResourceType review_article
Snippet Non-alcoholic fatty liver disease (NAFLD) is a series of diseases, involving excessive lipid deposition in the liver and is often accompanied by obesity,...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 1087260
SubjectTerms Diet
Endocrinology
exercise
Humans
medical treatment
Non-alcoholic Fatty Liver Disease - drug therapy
Non-alcoholic Fatty Liver Disease - therapy
non-alcoholic steatohepatitis
nonalcoholic fatty liver disease
Obesity - metabolism
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1NT9wwELWqPaBeEJQCgRa5Ug9FVbSJYzv2caGsECqcirQ3y18jVloFBOHAv2echO1uheDSa-Ioo5mJZ14884aQ78LKCIlP21uwORegc8WA5UFUEK2VsnCpOfnySp5f84uZmK2M-ko1YT09cK-4cSGs1wKDGk_cTEpZH6COCtMQHhA6-LT7YsxbAVPdHoywAYFE3yWDKEyPITYhNfsxlsrqatZxUv6NRB1h_2tZ5r_FkivRZ7pFNoe0kU56cbfJh9h8IhuXw8H4DrmY9Gf5XcManTcU8zq6LCKnt0AR5ue2n4c79xRs2z7RRSrKoMMZDf1xNZn-_nX8mVxPz_6cnufDmITci4q3uYNQSlZrxUuIQWrhRfCldjWg5hgEx5wMVlfWae-KwF0BmFFHCKqAMjpX7ZIRyhD3Ca1kwbzEIO8qxTXUiIUQHknlIm4EgbGMlC8qM37gEE-jLBYGsURSs-nUbJKazaDmjPxcPnPXM2i8ufokWWK5MrFfdxfQJ8zgE-Y9n8jItxc7Gvxa0hGIbeLt44NhdV1qhMxaZGSvt-vyVZVEAbjkGanXLL4my_qdZn7TMXJrpThC14P_Ifwh-ZhG2qffPKX8Qkbt_WP8iolP6446H38G8uf_7g
  priority: 102
  providerName: Directory of Open Access Journals
Title Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)
URI https://www.ncbi.nlm.nih.gov/pubmed/36726464
https://www.proquest.com/docview/2771940295
https://pubmed.ncbi.nlm.nih.gov/PMC9884828
https://doaj.org/article/05ac959104814088acdf7e86564d249c
Volume 13
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lj9MwELaWRUJcEG_CY2UkDiAUiB0_DwiVR1mt6J6o1JvlJ1SqUuhmJfbfM3bSiqIFiUsOiZPYM358n8czg9AzbkVMOZ62t8nWjCddK5poHXiborVCNC47J89OxfGcnSz44gBt0x2NAjy7lNrlfFLzzerVzx8Xb2HAv8mME9bb1yl2IfvxUZpPzElA6FfQVViZZB6osxHul5kZyIQu6XGJEKymgA0GP5q_fGZvrSoh_S_DoX8ep_xtfZreRDdGYIknQ0-4hQ5idxtdm42m8zvoZDJY-4tLG152GJAf3h0zx-uEu3VX2yFj7tLjZPv-Aq_ysQ08WnHw89PJ9POHF3fRfPrxy_vjekykUHvesr52KRBBpVaMpBiE5p4HT7STyXpNU3DUiWB1a532rgnMNQkwd0xBNYlE59p76BDqEB8g3IqGegEwwLWK6SSBLQGBEspFmCoCpRUiW5EZP0YZz8kuVgbYRhazKWI2WcxmFHOFXu7e-T7E2Phn6XdZE7uSOT52ubHefDXjcDMNh5ZxgEIsR_RSyvqQZFQAXlkAwukr9HSrRwPjKRtJbBfX52eGSkk0kGrNK3R_0OvuV62ACjDBKiT3NL5Xl_0n3fJbidmtlWJAbh_-V1Mfoes5u33e8SHiMTrsN-fxCWCg3h2VvQO4flqQo9LJfwGSKQSb
linkProvider Scholars Portal
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Advancements+in+the+treatment+of+non-alcoholic+fatty+liver+disease+%28NAFLD%29&rft.jtitle=Frontiers+in+endocrinology+%28Lausanne%29&rft.au=Rong%2C+Li&rft.au=Zou%2C+Junyan&rft.au=Ran%2C+Wei&rft.au=Qi%2C+Xiaohong&rft.date=2023-01-16&rft.issn=1664-2392&rft.eissn=1664-2392&rft.volume=13&rft_id=info:doi/10.3389%2Ffendo.2022.1087260&rft.externalDBID=n%2Fa&rft.externalDocID=10_3389_fendo_2022_1087260
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1664-2392&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1664-2392&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1664-2392&client=summon